Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
Clinical outcomes of stereotactic body radiotherapy in oligometastatic disease: a national real-world cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Teja Macarena, López Campos Fernando, Pinto Álvaro, Thuissard Israel J, González María, Esteban David, Ocanto Abrahams, Fernández Castalia, Gonsalves Daniela, Torres Lisselott, Garrido María Isabel, López Escarlata, Fernández Jaume, Aakki Loubna, Ristori Antonio, Begara José, Romero Zoghbi Sigfredo Elias, Andreescu Jon, Bezares Ana Belén, Mateos María, Berenguer Miguel Ángel, Rivas Daniel, González Del Portillo Elisabet, Andreu Cristina, Holgado Esther, Siva Shankar, Zamboglou Constantinos, Couñago Felipe
Аннотация
PURPOSE: We conducted the first multicentre Spanish real-world study assessing the efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic patients treated in routine clinical practice.
METHODS: This retrospective, multicentre observational study included oligometastatic patients with primary solid tumours treated with SBRT between 2020 and 2024 across 12 Spanish radiotherapy centres. The primary endpoint was 1-year progression-free survival (PFS). The secondary endpoints included overall survival (OS), local control (LC), and acute and late adverse events by CTCAE v.5.0.
RESULTS: 300 patients with 451 treated lesions were included. Median age was 69 years. After a median follow-up of 22 months, 1- and 2-year PFS were 45.1% and 36.3% respectively, with a median PFS of 11 months (95% CI, 9-13). The 1- and 2-year OS were 92% and 82.9% (median not reached), and 1- and 2-year LC were 90.5% and 85.5% respectively. Multivariable analyses showed significantly better PFS and OS in prostate cancer patients. Repeat and induced oligometastatic patients showed worse PFS than those with synchronous disease (HR 2.86, 95% CI 1.59-5.13; p<0.001 and HR 2.97, 95% CI 1.58-5.57; p<0.001, respectively). Visceral-only disease also correlated with worse PFS compared to bone-only metastases. Local control was poorer in lesions ≥5 cm compared to <5 cm (p<0.001). Grade ≥3 acute and late adverse events occurred in 0.7% and 1% of patients.
CONCLUSION: In this real-world multicentre cohort, SBRT to the oligometastases showed efficacy with minimal adverse events. Prognostic differences among subgroups underscore the importance of an adequate patient selection and individualized treatment strategies.
METHODS: This retrospective, multicentre observational study included oligometastatic patients with primary solid tumours treated with SBRT between 2020 and 2024 across 12 Spanish radiotherapy centres. The primary endpoint was 1-year progression-free survival (PFS). The secondary endpoints included overall survival (OS), local control (LC), and acute and late adverse events by CTCAE v.5.0.
RESULTS: 300 patients with 451 treated lesions were included. Median age was 69 years. After a median follow-up of 22 months, 1- and 2-year PFS were 45.1% and 36.3% respectively, with a median PFS of 11 months (95% CI, 9-13). The 1- and 2-year OS were 92% and 82.9% (median not reached), and 1- and 2-year LC were 90.5% and 85.5% respectively. Multivariable analyses showed significantly better PFS and OS in prostate cancer patients. Repeat and induced oligometastatic patients showed worse PFS than those with synchronous disease (HR 2.86, 95% CI 1.59-5.13; p<0.001 and HR 2.97, 95% CI 1.58-5.57; p<0.001, respectively). Visceral-only disease also correlated with worse PFS compared to bone-only metastases. Local control was poorer in lesions ≥5 cm compared to <5 cm (p<0.001). Grade ≥3 acute and late adverse events occurred in 0.7% and 1% of patients.
CONCLUSION: In this real-world multicentre cohort, SBRT to the oligometastases showed efficacy with minimal adverse events. Prognostic differences among subgroups underscore the importance of an adequate patient selection and individualized treatment strategies.